Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 30,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $3.34, for a total transaction of $100,200.00. Following the completion of the transaction, the director directly owned 6,158,287 shares of the company’s stock, valued at $20,568,678.58. This trade represents a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, August 4th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.25, for a total transaction of $97,500.00.
• On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX traded up $0.05 on Wednesday, hitting $3.38. The company had a trading volume of 14,014,654 shares, compared to its average volume of 18,045,133. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.77 and a 52 week high of $7.18. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -3.25 and a beta of 1.07. The firm has a 50 day moving average of $3.33 and a two-hundred day moving average of $3.34.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period in the previous year, the firm posted ($0.41) EPS. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.92 earnings per share for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Brighton Jones LLC grew its stake in shares of Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after purchasing an additional 6,699 shares during the last quarter. Royal Bank of Canada raised its position in Recursion Pharmaceuticals by 627.6% during the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock worth $1,423,000 after purchasing an additional 232,038 shares during the last quarter. AQR Capital Management LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth about $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock worth $953,000 after buying an additional 12,372 shares during the period. Finally, Focus Partners Wealth acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth about $77,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RXRX shares. Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a research report on Monday, August 17th. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.06.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.